<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Document</title>
    <!-- Font Awesome -->
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.9.0/css/all.min.css"
        integrity="sha512-q3eWabyZPc1XTCmF+8/LuE1ozpg5xxn7iO89yfSOd5/oKvyqLngoNGsx8jq92Y8eXJ/IRxQbEC+FGSYxtk2oiw=="
        crossorigin="anonymous" referrerpolicy="no-referrer" />
    <!-- Bootstrap CSS -->
    <link rel="stylesheet" href="css/bootstrap.min.css">
    <!-- Custom CSS -->
    <link rel="stylesheet" href="css/style.css">
</head>

<body>

    <div class="main_page5 position-relative fixedHeight">
        <div class="nav_orange">
            <div class="nav_orange_left">
                <h4 class="GothamBook mb-0">With extended PFS and tolerability supported by Real-world studies, consider all-oral Ixazomib (NINLARO) + Rd for your appropriate patients with RRMM<sup>1–4</sup></h4>
            </div>
            <div class="nav_orange_right">
                <img src="img/logo_orange.png" alt="">
            </div>
        </div>
        <!-- page 5 middle box -->
            <div class="page5_middle_box page36_middle_box mt-2">
                <img class="me-5" src="img/page_36_icon_1.svg" alt="">
                <div>
                    <h4 class="txt_orange GothamBook mt-1 mb-3">EXTENDED EFFICACY</h4>
                    <p class="d-flex align-items-start txt_blue GothamBook mb-2 fs-14"><img class="mt-2 me-2" src="img/li_1.svg" alt=""> <span>Ixazomib (NINLARO) + Rd demonstrated extended PFS vs placebo + Rd in the TOURMALINE-MM1 RCT, which is replicated in Realworld studies<sup>1–4</sup></span></p>
                    <p class="d-flex align-items-start ps-3 fs-14 txt_blue GothamBook mb-2"><img class="mt-2 me-2" src="img/li_1.svg" alt=""> <span>mPFS in the ITT population: 20.6 months vs 14.7 months (HR=0.74, P=0.01)</span></p>
                    <p class="d-flex fs-14 align-items-start ps-3 txt_blue GothamBook mb-2"><img class="mt-2 me-2" src="img/li_1.svg" alt=""> <span>mPFS in patients with high-risk cytogenetics: 21.7 months vs 9.7 months (HR=0.54)</span></p>
                </div>
            </div>
            <div class="page5_middle_box page36_middle_box">
                <img class="me-5" src="img/page_36_icon_2.svg" alt="">
                <div>
                    <h4 class="txt_orange GothamBook mt-1 mb-3">MANAGEABLE TOLERABILITY</h4>
                    <p class="d-flex fs-14 align-items-start txt_blue GothamBook mb-2"><img class="mt-2 me-2" src="img/li_1.svg" alt=""> <span>The tolerability of Ixazomib (NINLARO) + Rd has been demonstrated through clinical trials and Real-world evidence<sup>1,2,5</sup></span></p>
                </div>
            </div>
            <div class="page5_middle_box page36_middle_box">
                <img class="me-5" src="img/page_36_icon_3.svg" alt="">
                <div>
                    <h4 class="txt_orange GothamBook mt-1 mb-3">CONVENIENT ALL-ORAL, PI-BASED REGIMEN</h4>
                    <p class="d-flex fs-14 align-items-start txt_blue GothamBook mb-2"><img class="mt-2 me-2" src="img/li_1.svg" alt=""> <span>Ixazomib (NINLARO) is the first and only PI with the convenience of oral administration<sup>6</sup></span></p>
                </div>
            </div>
    </div>
        <!--  -->

            <div class="page5_middle_box page5_p_sm w-75 mb-1 mt-4">
                <p class="GothamLight">HR = hazard ratio; ITT = intent-to-treat; mPFS = median progression-free survival; PFS = progression-free survival; PI = proteasome inhibitor; RCT = randomised controlled trial; Rd = REVLIMID® (lenalidomide) + dexamethasone; RRMM = relapsed/refractory multiple myeloma.</p>
            </div>


            <div class="footer_page5">
                <div class="d-flex align-items-end">
                    <div class="page5_btns_md">
                        <a href="../page5/index.html"><p class="mb-0 position-relative">MM1 study design</p></a>
                        <a href="../page6/index.html"><p class="mb-0 position-relative">MM1 patient baseline characteristics</p></a>
                        <a href="../page8/index.html"><p class="mb-0 position-relative">RWE study Hajek et al.</p></a>
                        <a href="../page15/index.html"><p class="mb-0 position-relative">RWE study Terpos et al.</p></a>
                        <a href="../page11/index.html"><p class="mb-0 position-relative">RWE study Chari et al.</p></a>
                        <a href="../page18/index.html"><p class="mb-0 position-relative">RWE study Minarik et al.</p></a>
                        <a href="../page21/index.html"><p class="mb-0 position-relative">MM1 PFS</p></a>
                        <a href="../page23/index.html"><p class="mb-0 position-relative">MM1 PFS in patients with high-risk cytogenetics</p></a>
                        <a href="../page25/index.html"><p class="mb-0 position-relative">MM1 response rate</p></a>
                        <a href="../page28/index.html"><p class="mb-0 position-relative">MM1 PFS in <br> pre-treated patients</p></a>
                        <a href="../page31/index.html"><p class="mb-0 position-relative">MM1 safety data</p></a>
                        <a href="../page34/index.html"><p class="mb-0 position-relative">Dosing</p></a>
                        <a href="../page36/index.html"><p class="mb-0 position-relative">Summary</p></a>
                        <a href="../page38/index.html"><p class="mb-0 position-relative">MM6 data</p></a>
                        <a></a>
                    </div>
                    <div class="footer_inner_nav1 position-static ms-auto bg-transparent p-0">
                        <ul>
                            <li>
                                <a href="../page4/index.html"><img src="img/page_1_footer_icon_1.svg" alt=""></a>
                            </li>
                            <li>
                                <a href="https://onetakeda.app.box.com/s/reg7tviee8telgupc6cccshjet2wqqqh" target="_blank" class="text-uppercase">pi</a>
                            </li>
                            <li>
                                <a href="../page37/index.html" class="text-uppercase">ref</a>
                            </li>
                        </ul>
                    </div>
                </div>
            </div>
    </div>

</body>

</html>